No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 0 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T12:41:21.426Z. Latest historical point 2026-10-05.
The latest delayed quote for Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) stock was $10.19 as of Oct 5, 2026, 4:00 PM EDT, unchanged from the previous close.
Drugs Made In America Acquisition II Corp. currently lacks significant business operations.
Financial - Conglomerates · New York, NY
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
N/A
vs Estimate
N/A
Revenue
$0.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1DMII | $649.10M | $10.19 | +0.00% | N/A | N/A | N/A | N/A |
| 2ACNB | $651.32M | $63.78 | +0.00% | +51.31% | +21.57% | +12.71% | vs DMII |
| 3CBNK | $651.85M | $40.02 | -1.06% | +33.74% | +11.49% | N/A | vs DMII |
| 4CSHR | $637.82M | $4.84 | -2.22% | N/A | N/A | N/A | vs DMII |
| 5ABTC | $635.10M | $8.71 | +2.35% | -91.58% | -84.01% | N/A | vs DMII |
| 6BIT | $633.40M | $11.10 | -1.94% | -6.84% | -0.26% | +5.53% | vs DMII |
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$10.19
High
N/A
